Treatment of early diffuse systemic sclerosis skin disease

Tracy M. Frech*, Victoria K. Shanmugam, Ami A. Shah, Shervin Assassi, Jessica K. Gordon, Faye N. Hant, Monique E. Hinchcliff, Virginia Steen, Dinesh Khanna, Cristiane Kayser, Robyn T. Domsic

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


Diffuse systemic sclerosis carries a high morbidity and mortality. The Prospective Registry of Early Systemic Sclerosis (PRESS), a multicentre incident cohort study of patients with early diffuse cutaneous systemic sclerosis, has the goal of advancing the understanding of disease pathogenesis and identifying novel biomarkers. In this review, PRESS investigators discuss the evidence pertaining to the more commonly used treatments for early diffuse SSc skin disease including methotrexate, mycophenolate, cyclophosphamide, azathioprine, and intravenous immunoglobulin. This review highlights the unmet need for effective treatment in early diffuse SSc as well as its more rigorous study. Nonetheless, the PRESS investigators aim to decrease intra- and inter-institutional variability in prescribing in order to improve the understanding of the clinical course of early diffuse SSc skin disease.

Original languageEnglish (US)
Pages (from-to)S166-S171
JournalClinical and experimental rheumatology
Issue numberSUPPL.76
StatePublished - 2013


  • Scleroderma
  • Skin disease
  • Systemic sclerosis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Treatment of early diffuse systemic sclerosis skin disease'. Together they form a unique fingerprint.

Cite this